Amgen Inc. which can be found using ticker (AMGN) have now 27 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $405.00 and $200.00 calculating the mean target price we have $334.06. Given that the stocks previous close was at $281.36 this now indicates there is a potential upside of 18.7%. There is a 50 day moving average of $319.90 and the 200 day MA is $306.27. The company has a market capitalization of 152.45B. Currently the stock stands at: $278.76 USD
The potential market cap would be $181,003,973,583 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 35.6, revenue per share of $60.64 and a 4.6% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
